Eye Complication Concerns Cast Shadow Over Novo Nordisk and Eli Lilly Amid Stock Surge

Recent news has increasingly highlighted the role of GLP-1 receptor agonists (GLP-1RAs) in treating diabetes and obesity, focusing on potential risks associated with their use. A recent publication in the Journal of the American Medical Association - Ophthalmology, noted that semaglutide, a GLP-1RA, prescribed to nearly 2% of Americans, has raised concerns over potential eye-related complications.

According to the study, nine patients in the U.S. reported eye complications after taking Novo Nordisk's Ozempic or Eli Lilly's Mounjaro. These included incidents like sudden vision loss following the administration of semaglutide. The report suggests the rapid correction of blood sugar levels, rather than the drug itself, might be linked to these complications.

Experts stress the importance of gradual dosage increases and regular eye examinations to prevent such side effects. Despite inquiries, neither Novo Nordisk nor Eli Lilly have commented on these concerns.

Eli Lilly and Novo Nordisk remain key players in the weight-loss drug market. The popularity of semaglutide has bolstered the GLP-1RA sector. Novo Nordisk’s three semaglutide treatments, Ozempic, Rybelsus, and Wegovy, have shown significant revenue growth, suggesting the continued strong market presence and potential for further expansion.

Eli Lilly has also seen success with their GLP-1RA, Mounjaro, achieving over $11 billion in sales in 2024. As new indications get approved, the competition in the global pharmaceutical market, especially among obesity treatments, is intensifying.

The competition extends beyond Novo Nordisk and Eli Lilly, with other pharmaceutical giants joining the race, and in China, the competition is increasing as more companies enter the market. The patent expiration of key compounds like semaglutide creates further opportunities for new players to emerge.